NCT01595321 2024-08-14
Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
Clinical Trials
13 trialsNCT02352337 2024-07-10
PANOPTIMOX
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT02128100 2024-03-05
BCC-RAD-13
University of Louisville
Phase 2 Completed
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT02178709 2022-04-19
A Phase II Study of Neoadjuvant FOLFIRINOX
Indiana University
Phase 2 Completed
NCT01591733 2021-05-28
FOLFIRINOX + RT for Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Unknown
NCT03042780 2020-11-27
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01821729 2020-09-25
Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Unknown
NCT01896869 2020-05-19
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01661088 2019-11-13
A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT01688336 2017-10-06
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT01523457 2017-08-30
FOLFIRINOX
Yale University
Phase 2 Completed
NCT02243007 2017-05-16
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Terminated